

**REF: MDOL/CS-SE/2024-25/0027**

**October 11,2024**

**To,**  
Listing Department  
**BSE Ltd**  
1<sup>st</sup> Floor, New Trade Wing,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001

Listing Department  
**National Stock Exchange of India  
Limited**  
“Exchange Plaza”, 5<sup>th</sup> Floor,  
Plot No. C-1, Block G,  
Bandra - Kurla Complex,  
Bandra(E), Mumbai – 400 051

**Scrip Code: 532637**

**Symbol: MANGALAM**

**Subject: Intimation to Stock Exchange under Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 (“LODR Regulations”)**

**Reference: Participation in the CPhI held in Milan, 2024**

Dear Ma'am/Sir,

We are excited to announce its participation in the CPHI event, this took place from October 8-October 10, 2024 at the Fiera Milano exhibition center in Milan, Italy a premier platform for the pharmaceutical industry. This event provides an excellent opportunity for us to connect with key players in the sector, fostering relationships that will drive innovation and collaboration.

As we engage with industry leaders, we aim to explore new partnerships and enhance our network, positioning ourselves for positive growth in the coming years. Our participation reflects our commitment to not only advancing our own business goals but also contributing to the broader pharmaceutical landscape.

CPhI Milan stands as the world's largest international event dedicated to the pharmaceutical industry, uniting over 47,000 professionals and 2,600 exhibitors from more than 150 countries. This dynamic gathering encompasses the entire pharmaceutical supply chain, featuring key segments such as raw materials, finished products, machinery, biopharmaceuticals, and packaging solutions.

# Mangalam Drugs and Organics Limited



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.

☎ 91-22-62616200 / 6300 / 8787 ☎ 91-22-62619090 • CIN : L24230MH1972PLC116413

We look forward to sharing our insights, learning from others, and discovering new avenues for development as we work towards a successful future.

Thanking You,

Yours Faithfully,

For **Mangalam Drugs & Organics Limited**

**Govardhan M. Dhoot**

Managing Director

DIN: 01240086



## Mangalam Drugs and Organics Limited

One of the fastest growing Anti-Malaria API companies

Mangalam Drugs & Organics Limited commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and Intermediates at VAP in Gujarat in 1977. It has a multi-product manufacturing facility on two locations, and an in-house Research & Development laboratory recognized by the Department of Scientific Industrial Research, Government of India (DSIR).

### MANUFACTURING FACILITIES

ESTABLISHED IN 1977  
50<sup>th</sup> SCENARIO

## ACCREDITATIONS



### PRODUCT LIST

Sl. No.	Active Pharmaceutical Ingredients (APIs)	Pharmaceutical Intermediates (PIs)	Approval
1	Artemisinin Hydrochloride	Pharmaceutical Intermediates	USFDA
2	Artemether	Pharmaceutical Intermediates	USFDA
3	Artemonate	Pharmaceutical Intermediates	USFDA
4	Chloroquine	Pharmaceutical Intermediates	USFDA
5	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
6	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
7	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
8	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
9	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
10	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
11	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
12	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
13	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
14	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
15	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
16	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
17	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
18	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
19	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
20	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
21	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
22	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
23	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
24	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
25	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
26	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
27	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
28	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
29	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA
30	Hydroxychloroquine Sulfate	Pharmaceutical Intermediates	USFDA



Pharmaceutical Intermediates (PIs)	CAS No.	Sl. No.	Active Pharmaceutical Ingredients (APIs)	CAS No.
Product offering (Developed at R&D Scale) <td></td> <td></td> <td>Pipeline APIs ( Under Development )</td> <td></td>			Pipeline APIs ( Under Development )	
Hydroxy Na (H)	161193-60-7	1	Sulfadoxine Succinate (H)	106635-80-7
Hydroxy Na (H)			Hydroxy Na (H)	187235-37-6
			Hydroxy Na (H)	126113-96-9

